Symbols / BMRN Stock $56.47 +3.31% BioMarin Pharmaceutical Inc.

Healthcare • Biotechnology • United States • NMS
BMRN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Alexander Hardy
Exch · Country NMS · United States
Market Cap 10.91B
Enterprise Value 10.13B
Income 268.74M
Sales 3.24B
FCF (ttm) 459.42M
Book/sh 32.14
Cash/sh 11.50
Employees 3,221
Insider 10d —
IPO Jul 26, 1999
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 40.63
Forward P/E 8.74
PEG 0.66
P/S 3.37
P/B 1.76
P/C —
EV/EBITDA 16.05
EV/Sales 3.12
Quick Ratio 3.94
Current Ratio 5.81
Debt/Eq 23.17
LT Debt/Eq —
EPS (ttm) 1.39
EPS next Y 6.46
EPS Growth -43.10%
Revenue Growth 2.80%
EPS Gr Q/Q -43.20%
Rev Gr Q/Q —
Earnings (next) 2026-08-03
Earnings (prior) 2026-05-04
ROA 4.49%
ROE 4.48%
ROIC —
Gross Margin 51.16%
Oper. Margin 18.00%
Profit Margin 8.29%
Shs Outstand 193.28M
Shs Float 192.17M
Insider Own 0.30%
Instit Own 102.71%
Short Float 5.89%
Short Ratio 6.37
Short Interest 11.36M
52W High 66.28
vs 52W High -14.80%
52W Low 49.26
vs 52W Low 14.64%
Beta 0.23
Impl. Vol. 50.84%
Rel Volume 0.99
Avg Volume 2.05M
Volume 2.02M
Target (mean) $87.85
Tgt Median $85.50
Tgt Low $50.00
Tgt High $120.00
# Analysts 26
Recom Buy
Prev Close $54.66
Price $56.47
Change 3.31%
About

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$87.85
Mean price target
2. Current target
$56.47
Latest analyst target
3. DCF / Fair value
$42.78
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$56.47
Low
$50.00
High
$120.00
Mean
$87.85

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-22 main Canaccord Genuity Buy → Buy $111
2026-05-19 main B of A Securities Buy → Buy $80
2026-05-19 init Citigroup — → Buy $75
2026-05-18 main HC Wainwright & Co. Neutral → Neutral $50
2026-05-07 main Canaccord Genuity Buy → Buy $116
2026-05-05 main Bernstein Outperform → Outperform $82
2026-05-05 main Morgan Stanley Overweight → Overweight $119
2026-05-05 reit RBC Capital Sector Perform → Sector Perform $66
2026-05-05 main Evercore ISI Group Outperform → Outperform $120
2026-05-05 reit HC Wainwright & Co. Neutral → Neutral $55
2026-03-11 main B of A Securities Buy → Buy $85
2026-03-04 main Barclays Overweight → Overweight $105
2026-03-02 reit HC Wainwright & Co. Neutral → Neutral $55
2026-03-02 main Freedom Broker Buy → Buy $105
2026-02-26 main Canaccord Genuity Buy → Buy $104
2026-02-25 main Bernstein Outperform → Outperform $94
2026-02-25 main Guggenheim Buy → Buy $86
2026-02-25 main HC Wainwright & Co. Neutral → Neutral $55
2026-02-24 main Oppenheimer Outperform → Outperform $95
2026-02-18 main Wells Fargo Overweight → Overweight $75
News
RSS: Latest BMRN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-07 FRIBERG GREGORY R Officer — 3,281 $53.85 $176,682
2026-03-16 DAVIS GEORGE ERIC Officer — 14,570 $0.00 $0
2026-03-16 MUELLER BRIAN R Chief Financial Officer — 18,740 $0.00 $0
2026-03-16 GUYER CHARLES GREG Chief Technology Officer — 14,990 $0.00 $0
2026-03-16 HARDY ALEXANDER Chief Executive Officer — 62,440 $0.00 $0
2026-03-16 HUBBARD CRISTIN Officer — 15,410 $0.00 $0
2026-03-16 FRIBERG GREGORY R Officer — 19,150 $0.00 $0
2026-03-11 GUYER CHARLES GREG Chief Technology Officer — 16,486 $60.46 $996,744
2026-02-26 FRIBERG GREGORY R Officer — 6,326 $60.38 $381,937
2026-02-26 DAVIS GEORGE ERIC Officer — 26,061 $61.36 $1,599,103
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
3,221.25
+12.87%
2,853.91
+17.97%
2,419.23
+15.42%
2,096.04
Operating Revenue
3,221.25
+12.87%
2,853.91
+17.97%
2,419.23
+15.42%
2,096.04
Cost Of Revenue
717.44
+23.65%
580.24
+9.05%
532.06
+5.77%
503.02
Reconciled Cost Of Revenue
657.27
+24.70%
527.07
+7.59%
489.89
+5.61%
463.85
Gross Profit
2,503.81
+10.12%
2,273.68
+20.48%
1,887.16
+18.46%
1,593.02
Operating Expense
2,094.32
+16.39%
1,799.44
+5.76%
1,701.38
+10.80%
1,535.61
Research And Development
921.93
+23.39%
747.18
+0.06%
746.77
+14.96%
649.61
Selling General And Administration
1,153.00
+14.27%
1,009.00
+13.07%
892.40
+8.41%
823.20
Selling And Marketing Expense
530.20
+11.22%
476.70
-2.40%
488.40
+8.46%
450.30
General And Administrative Expense
622.80
+17.00%
532.30
+31.76%
404.00
+8.34%
372.90
Other Gand A
622.80
+17.00%
532.30
+31.76%
404.00
+8.34%
372.90
Total Expenses
2,811.76
+18.16%
2,379.68
+6.55%
2,233.45
+9.56%
2,038.63
Operating Income
409.50
-13.65%
474.24
+155.27%
185.78
+223.60%
57.41
Total Operating Income As Reported
409.48
-15.43%
484.21
+160.65%
185.77
+15.41%
160.97
EBITDA
572.94
-11.97%
650.86
+109.76%
310.28
+16.93%
265.36
Normalized EBITDA
572.94
-10.60%
640.86
+106.54%
310.28
+91.82%
161.76
Reconciled Depreciation
79.56
-17.49%
96.43
-7.63%
104.39
+2.37%
101.97
EBIT
493.38
-11.01%
554.43
+169.27%
205.90
+26.02%
163.39
Total Unusual Items
0.00
-100.00%
10.00
0.00
-100.00%
103.60
Total Unusual Items Excluding Goodwill
0.00
-100.00%
10.00
0.00
-100.00%
103.60
Special Income Charges
0.00
-100.00%
10.00
0.00
-100.00%
103.60
Restructuring And Mergern Acquisition
—
0.00
0.00
-100.00%
4.40
Net Income
348.90
-18.26%
426.86
+154.62%
167.65
+18.43%
141.56
Pretax Income
482.48
-10.94%
541.76
+187.31%
188.56
+26.07%
149.58
Net Non Operating Interest Income Expense
64.00
+2.87%
62.22
+51.73%
41.00
+1030.52%
3.63
Interest Expense Non Operating
10.90
-13.95%
12.67
-26.93%
17.34
+25.49%
13.81
Net Interest Income
64.00
+2.87%
62.22
+51.73%
41.00
+1030.52%
3.63
Interest Expense
10.90
-13.95%
12.67
-26.93%
17.34
+25.49%
13.81
Interest Income Non Operating
74.90
+0.03%
74.88
+28.36%
58.34
+223.49%
18.03
Interest Income
74.90
+0.03%
74.88
+28.36%
58.34
+223.49%
18.03
Other Income Expense
9.00
+68.74%
5.33
+113.95%
-38.22
-142.40%
90.14
Other Non Operating Income Expenses
9.00
+292.74%
-4.67
+87.78%
-38.22
-183.87%
-13.46
Tax Provision
133.58
+16.25%
114.90
+449.31%
20.92
+160.99%
8.02
Tax Rate For Calcs
0.00
+30.60%
0.00
+91.19%
0.00
+107.02%
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
2.12
0.00
-100.00%
5.55
Net Income Including Noncontrolling Interests
348.90
-18.26%
426.86
+154.62%
167.65
+18.43%
141.56
Net Income From Continuing Operation Net Minority Interest
348.90
-18.26%
426.86
+154.62%
167.65
+18.43%
141.56
Net Income From Continuing And Discontinued Operation
348.90
-18.26%
426.86
+154.62%
167.65
+18.43%
141.56
Net Income Continuous Operations
348.90
-18.26%
426.86
+154.62%
167.65
+18.43%
141.56
Normalized Income
348.90
-16.73%
418.98
+149.92%
167.65
+285.28%
43.51
Net Income Common Stockholders
348.90
-18.26%
426.86
+154.62%
167.65
+18.43%
141.56
Diluted EPS
1.80
-18.55%
2.21
+154.02%
0.87
+16.00%
0.75
Basic EPS
1.82
-19.11%
2.25
+152.81%
0.89
+17.11%
0.76
Basic Average Shares
191.79
+0.93%
190.03
+1.17%
187.83
+1.39%
185.27
Diluted Average Shares
197.39
+0.35%
196.71
+2.67%
191.59
+1.39%
188.96
Diluted NI Availto Com Stockholders
356.24
-17.95%
434.19
+158.99%
167.65
+18.43%
141.56
Average Dilution Earnings
7.33
+0.10%
7.33
0.00
0.00
Amortization
19.39
-55.18%
43.26
-30.47%
62.21
-0.94%
62.80
Amortization Of Intangibles Income Statement
19.39
-55.18%
43.26
-30.47%
62.21
-0.94%
62.80
Depreciation Amortization Depletion Income Statement
19.39
-55.18%
43.26
-30.47%
62.21
-0.94%
62.80
Depreciation And Amortization In Income Statement
19.39
-55.18%
43.26
-30.47%
62.21
-0.94%
62.80
Gain On Sale Of PPE
0.00
-100.00%
10.00
0.00
-100.00%
108.00
Total Other Finance Cost
—
0.39
-34.18%
0.59
+0.17%
0.59
Line Item Trend 2023-12-31
Total Assets
6,841.60
Current Assets
2,956.09
Cash Cash Equivalents And Short Term Investments
1,073.81
Cash And Cash Equivalents
755.13
Cash Equivalents
525.45
Cash Financial
229.68
Other Short Term Investments
318.68
Receivables
633.70
Accounts Receivable
633.70
Inventory
1,107.18
Raw Materials
155.70
Work In Process
571.11
Finished Goods
380.37
Other Current Assets
141.39
Total Non Current Assets
3,885.51
Net PPE
1,066.13
Gross PPE
1,933.22
Accumulated Depreciation
-867.09
Properties
0.00
Land And Improvements
117.56
Buildings And Improvements
860.81
Machinery Furniture Equipment
257.94
Construction In Progress
100.01
Other Properties
538.68
Leases
58.23
Goodwill And Other Intangible Assets
490.90
Goodwill
196.20
Other Intangible Assets
294.70
Investments And Advances
611.13
Non Current Deferred Assets
1,545.81
Non Current Deferred Taxes Assets
1,545.81
Other Non Current Assets
171.54
Total Liabilities Net Minority Interest
1,890.05
Current Liabilities
1,177.02
Payables And Accrued Expenses
434.83
Payables
428.64
Accounts Payable
315.51
Other Payable
110.48
Current Accrued Expenses
6.19
Pensionand Other Post Retirement Benefit Plans Current
201.07
Total Tax Payable
2.65
Income Tax Payable
2.65
Current Debt And Capital Lease Obligation
502.66
Current Debt
493.88
Other Current Borrowings
493.88
Current Capital Lease Obligation
8.78
Current Deferred Liabilities
4.62
Current Deferred Revenue
4.62
Other Current Liabilities
33.85
Total Non Current Liabilities Net Minority Interest
713.03
Long Term Debt And Capital Lease Obligation
593.10
Long Term Debt
593.10
Other Non Current Liabilities
119.94
Stockholders Equity
4,951.55
Common Stock Equity
4,951.55
Capital Stock
0.19
Common Stock
0.19
Share Issued
188.60
Ordinary Shares Number
188.60
Treasury Shares Number
0.00
Additional Paid In Capital
5,611.56
Retained Earnings
-621.55
Gains Losses Not Affecting Retained Earnings
-28.79
Other Equity Adjustments
-28.79
Total Equity Gross Minority Interest
4,951.55
Total Capitalization
5,544.64
Working Capital
1,779.06
Invested Capital
6,038.52
Total Debt
1,095.75
Net Debt
331.85
Capital Lease Obligations
8.78
Net Tangible Assets
4,460.65
Tangible Book Value
4,460.65
Available For Sale Securities
611.13
Investmentin Financial Assets
611.13
Other Equity Interest
-9.86
Unrealized Gain Loss
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
827.99
+44.54%
572.84
+259.69%
159.26
-9.46%
175.90
Cash Flow From Continuing Operating Activities
827.99
+44.54%
572.84
+259.69%
159.26
-9.46%
175.90
Net Income From Continuing Operations
348.90
-18.26%
426.86
+154.62%
167.65
+18.43%
141.56
Depreciation Amortization Depletion
79.56
-17.49%
96.43
-7.63%
104.39
+2.37%
101.97
Depreciation And Amortization
79.56
-17.49%
96.43
-7.63%
104.39
+2.37%
101.97
Other Non Cash Items
219.17
+832.88%
23.49
+514.54%
3.82
+1.19%
3.78
Stock Based Compensation
181.41
-10.00%
201.57
-2.67%
207.10
+5.50%
196.31
Provisionand Write Offof Assets
—
—
—
0.00
Asset Impairment Charge
244.22
+1127.91%
19.89
-48.48%
38.61
0.00
Deferred Tax
48.74
-13.12%
56.10
+224.71%
-44.98
+13.64%
-52.09
Deferred Income Tax
48.74
-13.12%
56.10
+224.71%
-44.98
+13.64%
-52.09
Operating Gains Losses
4.46
+116.67%
-26.75
-194.05%
28.45
+123.26%
-122.29
Net Foreign Currency Exchange Gain Loss
4.46
+126.62%
-16.75
-158.89%
28.45
+299.10%
-14.29
Change In Working Capital
-293.66
-35.70%
-216.40
+35.70%
-336.54
-249.17%
-96.38
Change In Receivables
-228.05
-293.81%
-57.91
+69.59%
-190.44
-132.14%
-82.03
Changes In Account Receivables
-228.05
-293.81%
-57.91
+69.59%
-190.44
-132.14%
-82.03
Change In Inventory
-116.93
-84.05%
-63.53
+59.55%
-157.06
-130.07%
-68.26
Change In Payables And Accrued Expense
66.14
+305.14%
-32.24
-146.82%
68.85
+16.66%
59.02
Change In Payable
66.14
+305.14%
-32.24
-146.82%
68.85
+16.66%
59.02
Change In Account Payable
66.14
+305.14%
-32.24
-146.82%
68.85
+16.66%
59.02
Change In Other Current Assets
-29.68
+61.69%
-77.48
+4.92%
-81.48
-576.95%
-12.04
Change In Other Current Liabilities
14.87
+0.73%
14.76
-37.41%
23.59
+240.18%
6.93
Investing Cash Flow
-414.24
-403.49%
136.49
+222.70%
-111.24
-455.41%
-20.03
Cash Flow From Continuing Investing Activities
-414.24
-403.49%
136.49
+222.70%
-111.24
-455.41%
-20.03
Net PPE Purchase And Sale
-103.04
-20.62%
-85.42
+11.65%
-96.69
+20.06%
-120.96
Purchase Of PPE
-103.04
-20.62%
-85.42
+11.65%
-96.69
+20.06%
-120.96
Capital Expenditure
-110.97
-13.92%
-97.42
+9.47%
-107.61
+18.19%
-131.54
Net Investment Purchase And Sale
-18.07
-108.11%
222.77
+6231.79%
-3.63
-144.38%
8.19
Purchase Of Investment
-355.88
+13.25%
-410.25
+52.76%
-868.50
-41.96%
-611.81
Sale Of Investment
337.80
-46.64%
633.02
-26.81%
864.86
+39.50%
620.00
Net Business Purchase And Sale
-285.19
0.00
0.00
—
Purchase Of Business
-285.19
0.00
0.00
—
Net Intangibles Purchase And Sale
-7.94
+33.83%
-11.99
-9.84%
-10.92
-3.20%
-10.58
Purchase Of Intangibles
-7.94
+33.83%
-11.99
-9.84%
-10.92
-3.20%
-10.58
Net Other Investing Changes
—
11.14
—
103.33
Financing Cash Flow
-42.39
+91.95%
-526.45
-2711.17%
-18.73
-0.41%
-18.65
Cash Flow From Continuing Financing Activities
-42.39
+91.95%
-526.45
-2711.17%
-18.73
-0.41%
-18.65
Net Issuance Payments Of Debt
0.00
+100.00%
-494.99
0.00
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
0.00
+100.00%
-494.99
0.00
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
0.00
+100.00%
-494.99
0.00
0.00
Net Long Term Debt Issuance
0.00
+100.00%
-494.99
0.00
0.00
Net Common Stock Issuance
—
—
—
0.00
Common Stock Payments
—
—
—
0.00
Repurchase Of Capital Stock
—
—
—
0.00
Proceeds From Stock Option Exercised
14.46
-70.66%
49.28
-28.95%
69.35
+0.03%
69.33
Net Other Financing Charges
-56.85
+29.58%
-80.74
+8.34%
-88.08
-0.11%
-87.98
Changes In Cash
371.36
+103.06%
182.88
+524.44%
29.29
-78.66%
137.22
Effect Of Exchange Rate Changes
-2.52
-152.19%
4.83
+269.27%
1.31
+3987.50%
0.03
Beginning Cash Position
942.84
+24.86%
755.13
+4.22%
724.53
+23.37%
587.28
End Cash Position
1,311.68
+39.12%
942.84
+24.86%
755.13
+4.22%
724.53
Free Cash Flow
717.02
+50.82%
475.42
+820.51%
51.65
+16.42%
44.36
Interest Paid Supplemental Data
7.25
-30.07%
10.36
+0.56%
10.30
+0.21%
10.28
Income Tax Paid Supplemental Data
96.20
+67.99%
57.27
-21.88%
73.31
+34.83%
54.37
Amortization Of Securities
-4.80
+42.47%
-8.35
+9.57%
-9.23
-403.25%
3.04
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category